|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | IMbrave150研究:免疫抑制剂治疗首次取得晚期肝细胞癌一线治疗成功显示文摘【据The New England Journal of Medicine 2020年5月报道】题:阿特朱单抗联合贝伐单抗在无法手术切除的晚期肝细胞癌中的疗效(作者Finn RS等)索拉非尼和仑伐替尼是目前晚期肝细胞癌(HCC)的标准一线治疗方案,可适当提高患者总生存率,但不良反应较多。PD-1抑制剂、阿特朱单抗(PD-L1抑制剂)以及贝伐单抗在Ⅰb期和Ⅱ期临床试验中显示出良好的客观缓解率。该研究探索了阿特朱单抗联合贝伐单抗对比单药索拉非尼治疗无法手术切除的晚期HCC的疗效和安全性。 | 刘昊天 钟鉴宏 FINN RS QIN S IKEDA M | 2020 | 临床肝胆病杂志2020，36，9： | 460 |
| 2 | The importance of avoiding unnecessary right ventricular pacing in clinical practice显示文摘Symptomatic bradycardia is effectively treated with the implantation of a cardiac pacemaker. Although a highly successful therapy, during recent years there has been a focus on the negative effects associated with longterm pacing of the apex of the right ventricle(RV). It has been shown in both experimental and clinical studies that RV pacing leads to ventricular dyssynchrony, similar to that of left bundle branch block, with subsequent detrimental effects on cardiac structure and function, and in some cases adverse clinical outcomes such as atrial fibrillation, heart failure and death. There is substantial evidence that patients with reduced left ventricular function(LVEF) are at particular high risk of suffering the detrimental clinical effects of long-term RV pacing. The evidence is, however, incomplete, coming largely from subanalyses of pacemaker and implantable cardiac defibrillator studies. In this group of patients with reduced LVEF and an expected high amount of RV pacing, biventricular pacing(cardiac resynchronization therapy) devices can prevent the negative effects of RV pacing and reduce ventricular dyssynchrony. Therefore, cardiac resynchronization therapy has emerged as an attractive option with promising results and more clinical studies are underway. Furthermore, specific pacemaker algorithms, which minimize RV pacing, can also reduce the negative effects of RV stimulation on cardiac function and may prevent clinical deterioration. | Finn Akerstrm Miguel A Arias Marta Pachón Jesús Jiménez-López Alberto Puchol Justo Juliá-Calvo | 2013 | World Journal of Cardiology2013，5，11： | 3 |
| 3 | Subcutaneous implantable defibrillator: State-of-the art 2013显示文摘The subcutaneous implantable cardioverter-defibrillator(S-ICD)has recently been approved for commercial use in Europe,New Zealand and the United States.It is comprised of a pulse generator,placed subcutaneously in a left lateral position,and a parasternal subcutaneous lead-electrode with two sensing electrodes separated by a shocking coil.Being an entirely subcutaneous system it avoids important periprocedural and long-term complications associated with transvenous implantable cardioverter-defibrillator(TV-ICD)systems as well as the need for fluoroscopy during implant surgery.Suitable candidates include pediatric patients with congenital heart disease that limits intracavitary lead placements,those with obstructed venous access,chronic indwelling catheters or high infection risk,as well as young patients with electrical heart disease(e.g.,Brugada Syndrome,long QT syndrome,and hypertrophic cardiomyopathy).Nevertheless,given the absence of intracavitary leads,the S-ICD is unable to offer pacing(apart from shortterm post-shock pacing).It is therefore not suitable in patients with an indication for antibradycardia pacing or cardiac resynchronization therapy,or with a history of repetitive monomorphic ventricular tachycardia that would benefit from antitachycardia pacing.Current data from initial clinical studies and post-commercialization'real-life'case series,including over 700 patients,have so far been promising and shown that the S-ICD successfully converts induced and spontaneous ventricular tachycardia/ventricular fibrillation episodes with associated complication and inappropriate shock rates similar to that of TV-ICDs.Furthermore,by using far-field electrograms better tachyarrhythmia discrimination when compared to TV-ICDs has been reported.Future results from ongoing clinical studies will determine the S-ICD system’s long-term performance,and better define suitable patient profiles. | Finn Akerstrm Miguel A Arias Marta Pachón Alberto Puchol Jesús Jiménez-Lópezl | 2013 | World Journal of Cardiology2013，5，9： | 2 |
| 4 | M/M/1 queue with working vacations (M/M/1/WV) 显示文摘 | Servi L Finn S | 2002 | Performance Eva-luation2002，，50： | 1 |
| 5 | M/M/1 queue with working vacations (M/M/1/WV)显示文摘 | Servi L D Finn S G | 2002 | Performance Evaluation2002，50，14： | 1 |
| 6 | Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging显示文摘 | Hanna J?rnum Elena G. Steffensen Linda Knutsson Ernst-Torben Fründ Carsten Wiberg Simonsen S?ren Lundbye-Christensen Ajit Shankaranarayanan David C. Alsop Finn Taageh?j Jensen Elna-Marie Larsson | 2010 | Neuroradiology2010，，4： | 1 |
| 7 | Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT) 显示文摘 | Shamshad F Kenchaiah S Finn PV | 2010 | Am Heart J2010，160，1： | 1 |
| 8 | On 'water' : unique reactivity of organic compounds in aqueous suspension 显示文摘 | NARAYAN S MULDOON J FINN M G | 2005 | Angewandte Chemie International Edition2005，44，22： | 1 |
| 9 | Durable hematologic complete responses can be achieved with lenalidomide in AL amy- loidosis 显示文摘 | Sanchorawala V Finn KT Fennessey S | 2010 | Blood2010，116，11： | 1 |
| 10 | Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398 显示文摘 | Browne G J Finn S G Proud C G | 2004 | J Biol Chem2004，279，12： | 1 |
| 11 | Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice显示文摘 | WYATT LR FINN DA KHOJA S | 2014 | Neurochem Res2014，39，6： | 1 |
| 12 | Adaptive detection mode with threshold control as a function of spatially sampled clutter- level estimates 显示文摘 | Finn H M Johnson R S | 1968 | RCA Review1968，29，9： | 1 |
| 13 | Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma显示文摘 | Finn S P Smyth P O' Leary J | 2003 | J Clin Endocrinol Metab2003，88，： | 1 |
| 14 | Adaptive detection mode with threshold control as a function of spatially sampled clutter-level estimates显示文摘 | Finn H M Johnson R S | 1968 | RCA Review1968，29，： | 1 |
| 15 | Adaptive detection mode with thresh old control as a function of spatially sampled clutter-level estimates显示文摘 | Finn H M Johnson R S | 1968 | RCA Review1968，29，9： | 1 |
| 16 | Pfam: clans, web tools and services显示文摘 | FINN R D MISTRY J BOCKLER B S | 2006 | Nucleic Acids Res2006，54，： | 1 |
| 17 | Increased dopaminergic and 5- hydroxytryptaminergic activities in male rat brain following long- term treatment with anabolic androgenic steroids 显示文摘 | Thiblin I Finn A Ross S B | 1999 | Br J Phar- macol1999，126，6： | 1 |
| 18 | Assessing the acid properties of desilicated ZSM-5 by FTIR using CO and 2,g,6-trimethypyridine (collidine) as molecular probes显示文摘 | Martin S H Stian S Finn J | 2009 | Appl Catal A2009，356，： | 1 |
| 19 | CONVERT : concurrent once - daily versus twice - daily radiotherapy - a new phase HI random- ized controlled trial for patients with limited - stage small cell lung cancer and good performance status 显示文摘 | Faivre - Finn C Falk S | 2009 | Lung Cancer2009，63，2： | 1 |
| 20 | Adaptive detection mode with threshold control as a function of spatially sampled clutterlevel estimates 显示文摘 | Finn H M Johnson R S | 1988 | RC Review1988，29，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员